Key result
Emerging therapies including nsMRAs, RNA therapies, GLP-1 RAs, and SGLT2 inhibitors offer novel BP-lowering strategies.
Why the study?
Current pharmacological approaches for hypertension do not fully satisfy patient needs, prompting clinical trials to investigate novel BP-lowering strategies.
What are the emerging pharmacological approaches for lowering high blood pressure in patients with arterial hypertension?
Design
Review
Authors
Loading...
Hypothesis-generating for resistant hypertension; leaves open the need for RCTs before any practice change.
What are the emerging pharmacological approaches for lowering high blood pressure in patients with arterial hypertension?
Emerging pharmacological therapies targeting the RAAS pathway and metabolic risk factors offer promising new strategies for managing uncontrolled and resistant hypertension.
Schinzari et al. (2025) conducted a review in Arterial Hypertension. Novel pharmacological approaches (non-steroidal MRAs, aldosterone synthase inhibitors, RNA-targeting therapies, GLP-1 RAs, SGLT2 inhibitors) was evaluated. Emerging pharmacological approaches, including non-steroidal mineralocorticoid receptor antagonists, RNA-targeting therapies, GLP-1 RAs, and SGLT2 inhibitors, offer novel strategies to lower blood pressure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: